RCM
SNDX icon

Riverhead Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Riverhead Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,199
Closed -$15K – 1579
2018
Q2 		$15K Buy
+2,199
New +$21.6K ﹤0.01% 1519

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Riverhead Capital Management's SNDX Position: Q3 2018 in Review

Riverhead Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2018, closing a stake of 2,199 shares — an estimated $15K sold.

Riverhead Capital Management first reported a position in SNDX in Q2 2018 and held it in 1 quarter. The position peaked at $15K in Q2 2018. 75 funds tracked by Wall St. Rank hold SNDX as of Q3 2018.

  • Riverhead Capital Management reported no remaining Syndax Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 2,199 Syndax Pharmaceuticals shares in Q3 2018, an estimated $15K.
  • Riverhead Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Riverhead Capital Management's Syndax Pharmaceuticals position peaked at $15K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2018.

Based on Riverhead Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.